Trial Profile
A Phase IIa Open-label Trial to Investigate the Early Bactericidal Activity, Safety and Tolerability of GSK3036656 in Participants With Drug-sensitive Pulmonary Tuberculosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Apr 2024
Price :
$35
*
At a glance
- Drugs GSK 3036656 (Primary) ; Rifampicin/isoniazid/pyrazinamide/ethambutol
- Indications Pulmonary tuberculosis
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 01 Mar 2024 Results assessing early bactericidal activity , safety and pharmacokinetics published in the Nature Medicine
- 21 Oct 2023 Number of treatment arms have been increased from 2to 5 by the addition of 2 more experimental arms for different doses of GSK3036656.
- 24 Mar 2023 Results of the popPK model and validate the 2SB model based on data from the monotherapy EBA study (NCT03557281) in drug-sensitive TB patients , presented at the 124th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics